Business Description
Cyteir Therapeutics Inc
NAICS : 541714
SIC : 2834
ISIN : US23284P1030
Description
Financial Strength
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 8077.63 | |||||
Equity-to-Asset | 0.95 | |||||
Interest Coverage | No Debt | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -18.1 | |||||
3-Year EPS without NRI Growth Rate | -19.2 | |||||
3-Year FCF Growth Rate | -10.1 |
Momentum Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 39.58 | |||||
9-Day RSI | 41.1 | |||||
14-Day RSI | 42.37 | |||||
6-1 Month Momentum % | -0.33 | |||||
12-1 Month Momentum % | 37.44 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 21.89 | |||||
Quick Ratio | 21.89 | |||||
Cash Ratio | 21.65 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -22.3 | |||||
Shareholder Yield % | 0.58 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROE % | -24.13 | |||||
ROA % | -23.09 | |||||
ROIC % | -971.43 | |||||
ROC (Joel Greenblatt) % | -4542.03 | |||||
ROCE % | -27.65 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PB Ratio | 0.87 | |||||
Price-to-Tangible-Book | 0.87 | |||||
EV-to-EBIT | 0.55 | |||||
EV-to-EBITDA | 0.55 | |||||
EV-to-FCF | 0.81 | |||||
Price-to-Net-Current-Asset-Value | 0.87 | |||||
Price-to-Net-Cash | 0.88 | |||||
Earnings Yield (Greenblatt) % | 181.82 | |||||
FCF Yield % | -23.8 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:CYTT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Cyteir Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | |||
EPS (TTM) ($) | -0.94 | ||
Beta | 0 | ||
Volatility % | 21.1 | ||
14-Day RSI | 42.37 | ||
14-Day ATR ($) | 0.010314 | ||
20-Day SMA ($) | 3.01 | ||
12-1 Month Momentum % | 37.44 | ||
52-Week Range ($) | 1.67 - 3.19 | ||
Shares Outstanding (Mil) | 36 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Cyteir Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Cyteir Therapeutics Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Cyteir Therapeutics Inc Frequently Asked Questions
What is Cyteir Therapeutics Inc(CYTT)'s stock price today?
When is next earnings date of Cyteir Therapeutics Inc(CYTT)?
Does Cyteir Therapeutics Inc(CYTT) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |